---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087630"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T05:41:36.330627+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fennec Q2 PEDMARK revenue $3.3M, up 98% QoQ; appoints Adrian Haigh as COO

## Summary
- Net product sales of PEDMARK $3.3M, a 98% sequential increase from Q1 2023.
- Net loss of $5.4M ($0.21/share) vs $5.1M ($0.19/share) in Q2 2022.
- Cash and equivalents $15.0M; management says sufficient for at least 12 months.
- Appointed Adrian Haigh as COO; he steps down from the board of directors.
- Management to present at Wedbush PacGrow Healthcare Conference on August 8-9, 2023.

## SEC filing metadata
- accession: 0001104659-23-087630
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465923087630/0001104659-23-087630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465923087630/tm2322902d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087630
- JSON: https://secwatch.observer/filing/0001104659-23-087630.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087630.txt

## Key facts
- Earnings Releases
  FENNEC PHARMACEUTICALS INC. reported second quarter ended June 30, 2023 results: revenue $3.3 million, net income $5.4 million ($0.21 per share), EPS ($0.21 per share).
  - Period: second quarter ended June 30, 2023
  - Revenue: $3.3 million
  - Net income: $5.4 million ($0.21 per share)
  - EPS: ($0.21 per share)
  - Result: reported results
  source text: 2023 and provided a business update. “During the second quarter, we continued to make strong progress with the U.S. commercial launch of PEDMARK ® , delivering net revenue of $3.3 million, which is a 98% increase in net revenue over the first quarter of 2023. These results reflect strong growth in patient starts and new account orders,” said Rosty Raykov, chief
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465923087630/0001104659-23-087630-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.